ArticleEuropean journal of orthopaedic surgery & traumatology : orthopedie traumatologie2026
Venous supercharging of the reverse sural artery flap prevents venous salvage procedures : a preliminary 63-case comparative series.
Article in European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare outcomes of standard and supercharged reverse sural artery flap (RSAF) for lower extremity reconstruction and define indications for each technique.
methodsRetrospective single-centre study of 63 patients (2013-2025) : 57 standard RSAFs (group C) and 6 supercharged RSAFs (group S). PRIMARY ENDPOINT: complete flap survival (absence of grade B, C or total necrosis). Secondary endpoints : partial necrosis grading, venous congestion, directed bleeding, hirudotherapy, and surgical revision.
resultsComplete flap survival was 87.7% (group C) and 100% (group S) (p = 1.000). Venous congestion occurred in 56.1% and 50.0% (p = 1.000). Directed bleeding (22.8%) and hirudotherapy (14.0%) were required in group C versus 0% in group S, where all episodes resolved spontaneously.
conclusionStandard RSAF is a robust, accessible first-line option for non-microsurgeons : 87.7% complete survival with a single total flap loss among 57 cases. Venous supercharging eliminates the need for postoperative venous salvage procedures and should be reserved for very high congestion risk or no viable reconstructive alternative.
Indexed as
Identifiers
42223697What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.